Your English writing platform
Discover LudwigExact(2)
We also compared the models for their classification of patients into the known PSA recurrence control and SYS progression case groups.
We compared the previously reported models for their classification of patients into the known PSA recurrence control and SYS progression case groups.
Similar(58)
Systemic (SYS) progression cases were men post-prostatectomy who developed systemic progression within 5 years after PSA recurrence.
The NED controls were matched to the systemic progression cases on birth-year, calendar year of RRP and initial diagnostic Gleason Score.
Of 18 (66.7%) progression cases, 12 were observed in patients with p53 positive immunolabelling.
In contrast to the first five listed features (filling-in, cortication, sclerosis, remodelling, and trabeculation), reconstitution of the normal structure was recorded more frequently in progression cases.
More importantly, recurrence was observed in 52.9% of our cases with p53 overexpression, and progression was noted in 12.3% of the patients, 66.7% of progression cases being observed in patients with p53-positive immunolabelling.
In reviewing the CA-125 results, our evaluation revealed that serological evaluation identified the highest number (74 initial detections and 20 confirmatory diagnoses, 61% of all recurrences) of disease progression cases.
To capture as many potential progression cases as possible, we also included 41 women with an index biopsy diagnosed as non-atypical EH SHH or CH) who received a diagnosis of CAH at hysterectomy at least 1 year later.
Given that aberrant activities of polyisoprenylated proteins play an important role in a majority of colon cancer progression cases [ 32] and PMPMEase inhibition has such a profound negative effect on cancer cell viability [ 33– 35], the current study was aimed at determining if PMPMEase may constitute a pharmacological target for bioactive anticancer agents such as curcumin.
Reasons for ceasing chemotherapy were patient refusal (six cases), attending doctors' decision for earlier local therapy (two cases), disease progression (one case) and ineligibility (one case).
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com